Alternative investments arm of Goldman Sachs, active here through its growth equity and life sciences teams.
Profile being verified
What they look for
Led the USD 100 M Series C of Neural Concept (Growth Equity team) and co-led the USD 152 M Series B of Vaderis Therapeutics with TCGX (Life Sciences team), where Colin Walsh sits on the board.
Recent investments
Recorded Swiss rounds: Neural Concept (Series C, USD 100 M, December 2025, lead), Vaderis Therapeutics (Series B, USD 152 M, August 2026, co-lead).
Rounds tracked by FundSwiss
- Vaderis TherapeuticsSeries B · USD 152 M
- Neural ConceptSeries C and later · USD 100 M